8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Feb 20, 2026·SEC
Material company update
Jan 28, 2026·SEC
Pasithea Therapeutics Corp.(KTTA)Earnings, Financials & Key Ratios
KTTA•NASDAQ
$0.54
Price updated Jun 27, 2026
AboutPasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.Show more
- Revenue$0
- EBITDA-$20M-48.5%
- Net Income-$20M-46.9%
- EPS (Diluted)-2.91+77.1%
- ROE-58.36%+19.9%
KTTA Price & Volume
Pasithea Therapeutics Corp. (KTTA) stock price & volume — 10-year historical chart
Loading chart...
Pre-Commercial Biotech Faces Persistent Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Healthy
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
"Pasithea Therapeutics remains a high-risk, pre-commercial entity entirely dependent on external capital to fund its neuro-oncology research, as evidenced by ten consecutive quarters of zero revenue. While a recent capital injection has bolstered the balance sheet to $50.4 million in cash, the firm's long-term viability remains tied to the binary success of its clinical pipeline. Investors should monitor the sustainability of this cash runway, as the company continues to report significant net losses, including $10.1 million in 2025Q4, without any offsetting commercial income."
Verdict Logic
the company's lack of revenue generation and persistent net losses, such as the $2.9 million loss reported in 2026Q1, present a binary risk profile that outweighs the current $50.4 million cash position.
KTTA Growth Metrics
Pasithea Therapeutics Corp. (KTTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-45.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.38%
Return on Capital
10 Years-41.68%
5 Years-44.92%
3 Years-60.48%
Last Year-59.41%
KTTA Recent Earnings
Pasithea Therapeutics Corp. (KTTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (40%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.12+73.3%
$0.45
Rev
—
$100,000
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.89-394.4%
$0.18
Rev
—
$100,000
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.18+0.0%
$0.18
Rev
—
$200,000
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.41
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.12vs $0.45+73.3% | —vs $100,000 |
| Q2 2026 | Mar 30, 2026 | $0.89vs $0.18-394.4% | —vs $100,000 |
| Q1 2026 | Feb 25, 2026 | $0.18vs $0.18+0.0% | —vs $200,000 |
| Q4 2025 | Nov 13, 2025 | $0.41 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Pasithea Therapeutics Corp. (KTTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.54 | $4.04M | -0.19 | — | — | -58.36% | — | |
| $14.82 | $1.42B | -4.81 | — | — | -151.02% | — | |
| $5.29 | $1.95B | -1.82 | 1227.6% | -19019.44% | -366.21% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — |
Compare KTTA vs Peers
Pasithea Therapeutics Corp. (KTTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KTTA SEC Filings & Documents
Pasithea Therapeutics Corp. (KTTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when KTTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KTTA Frequently Asked Questions
Pasithea Therapeutics Corp. (KTTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is KTTA profitable?
Pasithea Therapeutics Corp. (KTTA) reported a net loss of $19.7M for fiscal year 2025.
Dividend & Returns
What is KTTA's return on equity?
Pasithea Therapeutics Corp. (KTTA) has a return on equity (ROE) of -58.4%. Negative ROE indicates the company is unprofitable.
What is Pasithea Therapeutics Corp.'s free cash flow?
Pasithea Therapeutics Corp. (KTTA) had negative free cash flow of $16.9M in fiscal year 2025, likely due to heavy capital investments.